Companies/Stoke Therapeutics, Inc.

Company profile

Stoke Therapeutics, Inc.

NASDAQ: STOK · Healthcare · Biotechnology

PublicHQ Bedford, MACIK 0001623526Reports USD

#292 of 1,394 Healthcare companies by revenuetop-decile growth

EA Score

60C

FH 71DQ 37GM 69SS 62

v0.1 · 65/100 weight · provisional

↑ Altman-Z, 3-yr revenue growth · ↓ growth stability, disclosure history

Methodology →

Revenue TTM

$32.1M

Rev growth YoY (TTM)

-83.2%

Net income (FY)

-$6.9M

Employees

128

Market cap

$2.0B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$184.4M$184.4M2025

Net income-$6.9M-$6.9M2025

Operating income-$20.6M-$20.6M2025

Total assets$418.4M$418.4M2025

Liabilities$66.0M$66.0M2025

Equity$352.5M$352.5M2025

Revenue trend

FY2022 – FY2025 · USD

$12.4M

FY22

$8.8M

FY23

$36.6M

FY24

$184.4M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

License71%

Service29%

By geography

Not disclosed.

The read

Stoke Therapeutics, Inc. booked $184.4M in FY2025 revenue, growing 405% year over year — faster than 93% of Healthcare companies we track, at a -3.7% net margin.

Peers · Healthcare

Sarepta Therapeutics, Inc.69B Kodiak Sciences Inc.——Neogen Corporation65B Select Medical Holdings Corporation74B

Key facts

CEOIan F. Smith

SectorHealthcare

IndustryBiotechnology

HeadquartersBedford, MA

ExchangeNASDAQ: STOK

Employees128

IPO date2019-06-19

Latest filings

8-K2026-06-30 8-K2026-06-04 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-04-22 8-K2026-04-07 8-K2026-03-27 10-K2026-03-16

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.